STUDY OBJECTIVES: Serotonin (5-HT) has long been implicated in the control of sleep and wakefulness. This study evaluated the hypnotic efficacy of the 5-HT6 antagonist RO4368554 (RO) and the 5-HT2A receptor antagonist MDL100907 (MDL) relative to zolpidem. DESIGN: A randomized, repeated-measures design was utilized in which Wistar rats received intraperitoneal injections of RO (1.0, 3.0, and 10 mg/kg), MDL (0.1, 1.0 and 3.0 mg/kg), zolpidem (10 mg/kg), or vehicle in the middle of the dark (active) period. Electroencephalogram, electromyogram, body temperature (Tb) and locomotor activity were analyzed for 6 hours after injection. MEASUREMENTS AND RESULTS: RO, MDL, and zolpidem all produced significant increases in sleep and decreases in waking, compared with vehicle control. All 3 doses of MDL produced more consolidated sleep, increased non-rapid eye movement sleep (NREM) sleep, and increased electroencephalographic delta power during NREM sleep. The highest dose of RO (10.0 mg/kg) produced significant increases in sleep and decreases in waking during hour 2 following dosing. These increases in sleep duration were associated with greater delta power during NREM sleep. ZO Zolpidem induced sleep with the shortest latency and significantly increased NREM sleep and delta power but also suppressed rapid eye movement sleep sleep; in contrast, neither RO nor MDL affected rapid eye movement sleep. Whereas RO did not affect Tb, both zolpidem and MDL reduced Tb relative to vehicle-injected controls. CONCLUSIONS: These results support a role for 5-HT2A receptor modulation in NREM sleep and suggest a previously unrecognized role for 5-HT6 receptors in sleep-wake regulation.
STUDY OBJECTIVES:Serotonin (5-HT) has long been implicated in the control of sleep and wakefulness. This study evaluated the hypnotic efficacy of the 5-HT6 antagonist RO4368554 (RO) and the 5-HT2A receptor antagonist MDL100907 (MDL) relative to zolpidem. DESIGN: A randomized, repeated-measures design was utilized in which Wistar rats received intraperitoneal injections of RO (1.0, 3.0, and 10 mg/kg), MDL (0.1, 1.0 and 3.0 mg/kg), zolpidem (10 mg/kg), or vehicle in the middle of the dark (active) period. Electroencephalogram, electromyogram, body temperature (Tb) and locomotor activity were analyzed for 6 hours after injection. MEASUREMENTS AND RESULTS:RO, MDL, and zolpidem all produced significant increases in sleep and decreases in waking, compared with vehicle control. All 3 doses of MDL produced more consolidated sleep, increased non-rapid eye movement sleep (NREM) sleep, and increased electroencephalographic delta power during NREM sleep. The highest dose of RO (10.0 mg/kg) produced significant increases in sleep and decreases in waking during hour 2 following dosing. These increases in sleep duration were associated with greater delta power during NREM sleep. ZO Zolpidem induced sleep with the shortest latency and significantly increased NREM sleep and delta power but also suppressed rapid eye movement sleep sleep; in contrast, neither RO nor MDL affected rapid eye movement sleep. Whereas RO did not affect Tb, both zolpidem and MDL reduced Tb relative to vehicle-injected controls. CONCLUSIONS: These results support a role for 5-HT2A receptor modulation in NREM sleep and suggest a previously unrecognized role for 5-HT6 receptors in sleep-wake regulation.
Authors: I Léna; S Parrot; O Deschaux; S Muffat-Joly; V Sauvinet; B Renaud; M-F Suaud-Chagny; C Gottesmann Journal: J Neurosci Res Date: 2005-09-15 Impact factor: 4.164
Authors: L Rebecca Fish; Myra T Gilligan; Alexander C Humphries; Magnus Ivarsson; Tammy Ladduwahetty; Kevin J Merchant; Desmond O'Connor; Smita Patel; Elisabeth Philipps; Hugo M Vargas; Peter H Hutson; Angus M MacLeod Journal: Bioorg Med Chem Lett Date: 2005-08-15 Impact factor: 2.823
Authors: Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz Journal: Pharmacol Res Date: 2016-05-06 Impact factor: 7.658
Authors: Atom J Lesiak; Matthew Brodsky; Nathalie Cohenca; Alexandra G Croicu; John F Neumaier Journal: Mol Pharmacol Date: 2018-04-20 Impact factor: 4.436
Authors: Gregory S Parks; Deepti R Warrier; Lars Dittrich; Michael D Schwartz; Jeremiah B Palmerston; Thomas C Neylan; Stephen R Morairty; Thomas S Kilduff Journal: Neuropsychopharmacology Date: 2015-08-20 Impact factor: 7.853
Authors: Stephen R Morairty; Lars Dittrich; Ravi K Pasumarthi; Daniel Valladao; Jaime E Heiss; Dmitry Gerashchenko; Thomas S Kilduff Journal: Proc Natl Acad Sci U S A Date: 2013-11-04 Impact factor: 11.205